Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 23 Burkitt Lymphoma 19 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4 Leukemia, Biphenotypic, Acute 4 Leukemia 3 Recurrence 2 Neoplasm, Residual 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Blast Crisis 2 Philadelphia Chromosome 1 Lymphoma 1 Leukemia, Myeloid, Accelerated Phase 1 Leukemia, Myeloid 1 Leukemia, Lymphoid 1 Hematologic Neoplasms 1 Down Syndrome 1

Interventions

Cyclophosphamide 28 fludarabine 19 Rituximab 17 obinutuzumab 12 venetoclax 10 Lenalidomide 9 Bendamustine Hydrochloride 9 Prednisone 7 zanubrutinib 6 Doxorubicin 6 Blood Specimen Collection 6 pembrolizumab 5 ibrutinib 5 fludarabine phosphate 5 Biopsy 5 glofitamab 4 Vincristine 4 Trimethoprim, Sulfamethoxazole Drug Combination 4 Exercise 4 loncastuximab tesirine 3 gamma-Globulins 3 axicabtagene ciloleucel 3 acalabrutinib 3 Temozolomide 3 Surveys and Questionnaires 3 Palliative Care 3 Mycophenolic Acid 3 Methotrexate 3 Mesna 3 Magnetic Resonance Spectroscopy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Lymphoma × blinatumomab × Clear all

NCT07294677 2026-03-04

CAVALRY

University of Chicago

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡